Skip to main page content
  1. Kadiyala P, Li D, Nuñez FM, Altshuler D, Doherty R, Kuai R, Yu M, Kamran N, Edwards M, Moon JJ, Lowenstein PR, Castro MG, Schwendeman A. High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme. ACS Nano. 2019 Feb 26;13(2):1365-1384. doi: 10.1021/acsnano.8b06842. Epub 2019 Feb 11. PubMed PMID: 30721028; PubMed Central PMCID: PMC6484828.
  2. Núñez FJ, Mendez FM, Kadiyala P, Alghamri MS, Savelieff MG, Garcia-Fabiani MB, Haase S, Koschmann C, Calinescu AA, Kamran N, Saxena M, Patel R, Carney S, Guo MZ, Edwards M, Ljungman M, Qin T, Sartor MA, Tagett R, Venneti S, Brosnan-Cashman J, Meeker A, Gorbunova V, Zhao L, Kremer DM, Zhang L, Lyssiotis CA, Jones L, Herting CJ, Ross JL, Hambardzumyan D, Hervey-Jumper S, Figueroa ME, Lowenstein PR, Castro MG. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Sci Transl Med. 2019 Feb 13;11(479). doi: 10.1126/scitranslmed.aaq1427. PubMed PMID: 30760578; PubMed Central PMCID: PMC6400220.
  3. Núñez FJ, Mendez FM, Garcia-Fabiani MB, Pardo J, Edwards M, Lowenstein PR, Castro MG. Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures. J Vis Exp. 2019 Jan 9;(143). doi: 10.3791/58931. PubMed PMID: 30688315; PubMed Central PMCID: PMC6352905.
  4. Haase S, Garcia-Fabiani MB, Carney S, Altshuler D, Núñez FJ, Méndez FM, Núñez F, Lowenstein PR, Castro MG. Mutant ATRX: uncovering a new therapeutic target for glioma. Expert Opin Ther Targets. 2018 Jul;22(7):599-613. doi: 10.1080/14728222.2018.1487953. Epub 2018 Jun 20. Review. PubMed PMID: 29889582; PubMed Central PMCID: PMC6044414.
  5. Kamran N, Chandran M, Lowenstein PR, Castro MG. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy. Clin Immunol. 2018 Apr;189:34-42. doi: 10.1016/j.clim.2016.10.008. Epub 2016 Oct 21. Review. PubMed PMID: 27777083; PubMed Central PMCID: PMC5400737.
  6. Lowenstein PR, Castro MG. Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients. Clin Immunol. 2018 Apr;189:43-51. doi: 10.1016/j.clim.2017.07.006. Epub 2017 Jul 15. Review. PubMed PMID: 28720549; PubMed Central PMCID: PMC5768465.
  7. Kamran N, Alghamri MS, Nunez FJ, Shah D, Asad AS, Candolfi M, Altshuler D, Lowenstein PR, Castro MG. Current state and future prospects of immunotherapy for glioma. Immunotherapy. 2018 Feb 1;10(4):317-339. doi: 10.2217/imt-2017-0122. Review. PubMed PMID: 29421984; PubMed Central PMCID: PMC5810852.
  8. Mendez FM, Núñez FJ, Zorrilla-Veloz RI, Lowenstein PR, Castro MG. Native Chromatin Immunoprecipitation Using Murine Brain Tumor Neurospheres. J Vis Exp. 2018 Jan 29;(131). doi: 10.3791/57016. PubMed PMID: 29443090; PubMed Central PMCID: PMC5912236.
  9. Li D, Fawaz MV, Morin EE, Ming R, Sviridov D, Tang J, Ackermann R, Olsen K, Remaley AT, Schwendeman A. Effect of Synthetic High Density Lipoproteins Modification with Polyethylene Glycol on Pharmacokinetics and Pharmacodynamics. Mol Pharm. 2018 Jan 2;15(1):83-96. doi: 10.1021/acs.molpharmaceut.7b00734. Epub 2017 Nov 29. PubMed PMID: 29141139; PubMed Central PMCID: PMC6435036.
  10. Kamran N, Li Y, Sierra M, Alghamri MS, Kadiyala P, Appelman HD, Edwards M, Lowenstein PR, Castro MG. Melanoma induced immunosuppression is mediated by hematopoietic dysregulation. Oncoimmunology. 2018;7(3):e1408750. doi: 10.1080/2162402X.2017.1408750. eCollection 2018. PubMed PMID: 29399415; PubMed Central PMCID: PMC5790391.
  11. Tang J, Kuai R, Yuan W, Drake L, Moon JJ, Schwendeman A. Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting. Nanomedicine. 2017 Aug;13(6):1869-1878. doi: 10.1016/j.nano.2017.04.009. Epub 2017 Apr 18. PubMed PMID: 28434931; PubMed Central PMCID: PMC5554706.
  12. Chandran M, Candolfi M, Shah D, Mineharu Y, Yadav VN, Koschmann C, Asad AS, Lowenstein PR, Castro MG. Single vs. combination immunotherapeutic strategies for glioma. Expert Opin Biol Ther. 2017 May;17(5):543-554. doi: 10.1080/14712598.2017.1305353. Epub 2017 Mar 20. Review. PubMed PMID: 28286975; PubMed Central PMCID: PMC5451096.
  13. Kuai R, Ochyl LJ, Bahjat KS, Schwendeman A, Moon JJ. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater. 2017 Apr;16(4):489-496. doi: 10.1038/nmat4822. Epub 2016 Dec 26. PubMed PMID: 28024156; PubMed Central PMCID: PMC5374005.
  14. Ashley SL, Pretto CD, Stier MT, Kadiyala P, Castro-Jorge L, Hsu TH, Doherty R, Carnahan KE, Castro MG, Lowenstein PR, Spindler KR. Matrix Metalloproteinase Activity in Infections by an Encephalitic Virus, Mouse Adenovirus Type 1. J Virol. 2017 Mar 15;91(6). doi: 10.1128/JVI.01412-16. Print 2017 Mar 15. PubMed PMID: 28053109; PubMed Central PMCID: PMC5331797.
  15. Calinescu AA, Yadav VN, Carballo E, Kadiyala P, Tran D, Zamler DB, Doherty R, Srikanth M, Lowenstein PR, Castro MG. Survival and Proliferation of Neural Progenitor-Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12/CXCR4 Autocrine-Positive Feedback Mechanism. Clin Cancer Res. 2017 Mar 1;23(5):1250-1262. doi: 10.1158/1078-0432.CCR-15-2888. Epub 2016 Aug 19. PubMed PMID: 27542769; PubMed Central PMCID: PMC5316506.
  16. Koschmann C, Nunez FJ, Mendez F, Brosnan-Cashman JA, Meeker AK, Lowenstein PR, Castro MG. Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer. Cancer Res. 2017 Jan 15;77(2):227-233. doi: 10.1158/0008-5472.CAN-16-2301. Epub 2017 Jan 6. Review. PubMed PMID: 28062403; PubMed Central PMCID: PMC5243833.
  17. Kamran N, Kadiyala P, Saxena M, Candolfi M, Li Y, Moreno-Ayala MA, Raja N, Shah D, Lowenstein PR, Castro MG. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy. Mol Ther. 2017 Jan 4;25(1):232-248. doi: 10.1016/j.ymthe.2016.10.003. Epub 2017 Jan 4. PubMed PMID: 28129117; PubMed Central PMCID: PMC5363306.
  18. Yadav VN, Zamler D, Baker GJ, Kadiyala P, Erdreich-Epstein A, DeCarvalho AC, Mikkelsen T, Castro MG, Lowenstein PR. CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study. Oncotarget. 2016 Dec 13;7(50):83701-83719. doi: 10.18632/oncotarget.13295. PubMed PMID: 27863376; PubMed Central PMCID: PMC5341257.
  19. Yuan Y, Wen J, Tang J, Kan Q, Ackermann R, Olsen K, Schwendeman A. Synthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin. Int J Nanomedicine. 2016;11:6229-6238. doi: 10.2147/IJN.S112835. eCollection 2016. PubMed PMID: 27920529; PubMed Central PMCID: PMC5125756.
  20. Koschmann C, Zamler D, MacKay A, Robinson D, Wu YM, Doherty R, Marini B, Tran D, Garton H, Muraszko K, Robertson P, Leonard M, Zhao L, Bixby D, Peterson L, Camelo-Piragua S, Jones C, Mody R, Lowenstein PR, Castro MG. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma. Oncotarget. 2016 Oct 4;7(40):65696-65706. doi: 10.18632/oncotarget.11602. PubMed PMID: 27582545; PubMed Central PMCID: PMC5323185.
  21. Lowenstein PR, Castro MG. Multiple Expressed Endogenous Glioma Epitopes as Novel Vaccines for Gliomas. Clin Cancer Res. 2016 Oct 1;22(19):4760-4762. doi: 10.1158/1078-0432.CCR-16-1477. Epub 2016 Aug 12. PubMed PMID: 27521444; PubMed Central PMCID: PMC5076016.
  22. Kamran N, Calinescu A, Candolfi M, Chandran M, Mineharu Y, Asad AS, Koschmann C, Nunez FJ, Lowenstein PR, Castro MG. Recent advances and future of immunotherapy for glioblastoma. Expert Opin Biol Ther. 2016 Oct;16(10):1245-64. doi: 10.1080/14712598.2016.1212012. Epub 2016 Jul 27. Review. PubMed PMID: 27411023; PubMed Central PMCID: PMC5014608.
  23. Wilson TJ, Zamler DB, Doherty R, Castro MG, Lowenstein PR. Reversibility of glioma stem cells' phenotypes explains their complex in vitro and in vivo behavior: Discovery of a novel neurosphere-specific enzyme, cGMP-dependent protein kinase 1, using the genomic landscape of human glioma stem cells as a discovery tool. Oncotarget. 2016 Sep 27;7(39):63020-63041. doi: 10.18632/oncotarget.11589. PubMed PMID: 27564115; PubMed Central PMCID: PMC5325344.
  24. Baker GJ, Chockley P, Zamler D, Castro MG, Lowenstein PR. Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells. Oncoimmunology. 2016 Jun;5(6):e1163461. doi: 10.1080/2162402X.2016.1163461. eCollection 2016 Jun. PubMed PMID: 27471637; PubMed Central PMCID: PMC4938363.
  25. Calinescu AA, Castro MG. Microtubule targeting agents in glioma. Transl Cancer Res. 2016 Jun;5(Suppl 1):S54-S60. doi: 10.21037/tcr.2016.06.12. PubMed PMID: 30680290; PubMed Central PMCID: PMC6342473.
  26. VanderVeen N, Raja N, Yi E, Appelman H, Ng P, Palmer D, Zamler D, Dzaman M, Lowenstein PR, Castro MG. Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model. Hum Gene Ther Methods. 2016 Jun;27(3):98-111. doi: 10.1089/hgtb.2015.168. Epub 2016 Apr 28. PubMed PMID: 27056322; PubMed Central PMCID: PMC4926229.
  27. Lowenstein PR, Castro MG. The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors. Adv Pharmacol. 2016;76:147-73. doi: 10.1016/bs.apha.2016.03.002. Epub 2016 Apr 23. Review. PubMed PMID: 27288077; PubMed Central PMCID: PMC4997808.
  28. Kuai R, Li D, Chen YE, Moon JJ, Schwendeman A. High-Density Lipoproteins: Nature's Multifunctional Nanoparticles. ACS Nano. 2016 Mar 22;10(3):3015-41. doi: 10.1021/acsnano.5b07522. Epub 2016 Feb 25. Review. PubMed PMID: 26889958; PubMed Central PMCID: PMC4918468.
  29. Koschmann C, Calinescu AA, Nunez FJ, Mackay A, Fazal-Salom J, Thomas D, Mendez F, Kamran N, Dzaman M, Mulpuri L, Krasinkiewicz J, Doherty R, Lemons R, Brosnan-Cashman JA, Li Y, Roh S, Zhao L, Appelman H, Ferguson D, Gorbunova V, Meeker A, Jones C, Lowenstein PR, Castro MG. ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. Sci Transl Med. 2016 Mar 2;8(328):328ra28. doi: 10.1126/scitranslmed.aac8228. PubMed PMID: 26936505; PubMed Central PMCID: PMC5381643.
  30. Kamran N, Candolfi M, Baker GJ, Ayala MM, Dzaman M, Lowenstein PR, Castro MG. Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms. Methods Mol Biol. 2016;1382:467-82. doi: 10.1007/978-1-4939-3271-9_31. PubMed PMID: 26611605; PubMed Central PMCID: PMC4677484.
  31. Lowenstein PR, Castro MG. The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors . In: Advances in Pharmacology. Schwarcz R, editor. Burlington USA: Elesvier Inc.; 2016. Chapter 7; p.147-173.
  32. Subramanian C, Kuai R, Zhu Q, White P, Moon JJ, Schwendeman A, Cohen MS. Synthetic high-density lipoprotein nanoparticles: A novel therapeutic strategy for adrenocortical carcinomas. Surgery. 2016 Jan;159(1):284-94. doi: 10.1016/j.surg.2015.08.023. Epub 2015 Nov 12. PubMed PMID: 26582501; PubMed Central PMCID: PMC4709032.
  33. Subramanian C, Kuai R, Zhu Q, White P, Moon J, Schwendeman A, Cohen MS. Novel HDL nanoparticle as combination therapy with chemotherapeutics for adrenocortical carcinoma. [Print]. J. Surgery,; 2016. .
  34. Baker GJ, Castro MG, Lowenstein PR. Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells. J Vis Exp. 2015 Nov 28;(105). doi: 10.3791/53676. PubMed PMID: 26650233; PubMed Central PMCID: PMC4692754.
  35. Calinescu AA, Núñez FJ, Koschmann C, Kolb BL, Lowenstein PR, Castro MG. Transposon mediated integration of plasmid DNA into the subventricular zone of neonatal mice to generate novel models of glioblastoma. J Vis Exp. 2015 Feb 22;(96). doi: 10.3791/52443. PubMed PMID: 25741859; PubMed Central PMCID: PMC4354658.
  36. Lowenstein PR, Castro MG. Glioma trials and viral tribulations: can anything be concluded from non-controlled trials?. J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):125. doi: 10.1136/jnnp-2014-308406. Epub 2014 Oct 3. PubMed PMID: 25280917; PubMed Central PMCID: PMC4677476.
  37. Calinescu AA, Kamran N, Baker G, Mineharu Y, Lowenstein PR, Castro MG. Overview of current immunotherapeutic strategies for glioma. Immunotherapy. 2015;7(10):1073-104. doi: 10.2217/imt.15.75. Review. PubMed PMID: 26598957; PubMed Central PMCID: PMC4681396.
  38. Gene Therapy Approaches Using REproducible and Fully Penetrant Lentivirus-Mediated Endogenous Glioma Models . In: Springer Protocols Neuromethods. 98 ed. Bo X, Verhaagen J, editors. New York: Humana Press; 2015. Chapter 14; p.341-354. 359p.
  39. Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014 Oct;3(9):e955691. doi: 10.4161/21624011.2014.955691. eCollection 2014 Oct. Review. PubMed PMID: 25941621; PubMed Central PMCID: PMC4292729.
  40. Mineharu Y, Kamran N, Lowenstein PR, Castro MG. Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions. Mol Cancer Ther. 2014 Dec;13(12):3024-36. doi: 10.1158/1535-7163.MCT-14-0400. Epub 2014 Sep 25. PubMed PMID: 25256739; PubMed Central PMCID: PMC4258521.
  41. Castro MG, Baker GJ, Lowenstein PR. Blocking immunosuppressive checkpoints for glioma therapy: the more the Merrier!. Clin Cancer Res. 2014 Oct 15;20(20):5147-9. doi: 10.1158/1078-0432.CCR-14-0820. Epub 2014 May 30. PubMed PMID: 24879798; PubMed Central PMCID: PMC4330468.
  42. Baker GJ, Chockley P, Yadav VN, Doherty R, Ritt M, Sivaramakrishnan S, Castro MG, Lowenstein PR. Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity. Cancer Res. 2014 Sep 15;74(18):5079-90. doi: 10.1158/0008-5472.CAN-14-1203. Epub 2014 Jul 18. PubMed PMID: 25038230; PubMed Central PMCID: PMC4184887.
  43. Castro MG, Candolfi M, Wilson TJ, Calinescu A, Paran C, Kamran N, Koschmann C, Moreno-Ayala MA, Assi H, Lowenstein PR. Adenoviral vector-mediated gene therapy for gliomas: coming of age. Expert Opin Biol Ther. 2014 Sep;14(9):1241-57. doi: 10.1517/14712598.2014.915307. Epub 2014 Apr 29. Review. PubMed PMID: 24773178; PubMed Central PMCID: PMC4127140.
  44. Lynes J, Wibowo M, Koschmann C, Baker GJ, Saxena V, Muhammad AK, Bondale N, Klein J, Assi H, Lieberman AP, Castro MG, Lowenstein PR. Lentiviral-induced high-grade gliomas in rats: the effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H. Neurotherapeutics. 2014 Jul;11(3):623-35. doi: 10.1007/s13311-014-0269-y. PubMed PMID: 24752661; PubMed Central PMCID: PMC4121445.
  45. Baker GJ, Yadav VN, Motsch S, Koschmann C, Calinescu AA, Mineharu Y, Camelo-Piragua SI, Orringer D, Bannykh S, Nichols WS, deCarvalho AC, Mikkelsen T, Castro MG, Lowenstein PR. Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia. 2014 Jul;16(7):543-61. doi: 10.1016/j.neo.2014.06.003. PubMed PMID: 25117977; PubMed Central PMCID: PMC4198934.
  46. Assi HH, Paran C, VanderVeen N, Savakus J, Doherty R, Petruzzella E, Hoeschele JD, Appelman H, Raptis L, Mikkelsen T, Lowenstein PR, Castro MG. Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy. J Pharmacol Exp Ther. 2014 Jun;349(3):458-69. doi: 10.1124/jpet.114.214619. Epub 2014 Apr 2. PubMed PMID: 24696041; PubMed Central PMCID: PMC4019317.
  47. Assi H, Espinosa J, Suprise S, Sofroniew M, Doherty R, Zamler D, Lowenstein PR, Castro MG. Assessing the role of STAT3 in DC differentiation and autologous DC immunotherapy in mouse models of GBM. PLoS One. 2014;9(5):e96318. doi: 10.1371/journal.pone.0096318. eCollection 2014. PubMed PMID: 24806510; PubMed Central PMCID: PMC4013007.
  48. Candolfi M, Yagiz K, Wibowo M, Ahlzadeh GE, Puntel M, Ghiasi H, Kamran N, Paran C, Lowenstein PR, Castro MG. Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models. Clin Cancer Res. 2014 Mar 15;20(6):1555-1565. doi: 10.1158/1078-0432.CCR-13-2140. Epub 2014 Feb 5. PubMed PMID: 24501391; PubMed Central PMCID: PMC3959570.
  49. VanderVeen N, Paran C, Appelhans A, Krasinkiewicz J, Lemons R, Appelman H, Doherty R, Palmer D, Ng P, Lowenstein PR, Castro MG. Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors. Mol Ther Methods Clin Dev. 2014 Feb 5;1. doi: 10.1038/mtm.2013.10. PubMed PMID: 25068145; PubMed Central PMCID: PMC4111110.
  50. Lowenstein PR, Yadav VN, Chockley P, Castro M. There must be a way out of here: identifying a safe and efficient combination of promoter, transgene, and vector backbone for gene therapy of neurological disease. Mol Ther. 2014 Feb;22(2):246-247. doi: 10.1038/mt.2013.297. PubMed PMID: 24487564; PubMed Central PMCID: PMC3918918.